MX2020002310A - Formas de dosificacion de alta concentracion de pridopidina. - Google Patents

Formas de dosificacion de alta concentracion de pridopidina.

Info

Publication number
MX2020002310A
MX2020002310A MX2020002310A MX2020002310A MX2020002310A MX 2020002310 A MX2020002310 A MX 2020002310A MX 2020002310 A MX2020002310 A MX 2020002310A MX 2020002310 A MX2020002310 A MX 2020002310A MX 2020002310 A MX2020002310 A MX 2020002310A
Authority
MX
Mexico
Prior art keywords
pridopidine
dosage forms
high concentration
concentration dosage
dosage form
Prior art date
Application number
MX2020002310A
Other languages
English (en)
Inventor
Danit Licht
Ioana Lovinger
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2020002310A publication Critical patent/MX2020002310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona una forma de dosificación unitaria sólida que comprende pridopidina y al menos un excipiente farmacéuticamente aceptable, en donde la forma de dosificación tiene un volumen y en donde la proporción de la cantidad de pridopidina al volumen de la forma de dosificación es 135-600 mg/ml.
MX2020002310A 2017-08-30 2018-08-30 Formas de dosificacion de alta concentracion de pridopidina. MX2020002310A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762552071P 2017-08-30 2017-08-30
PCT/US2018/048831 WO2019046568A1 (en) 2017-08-30 2018-08-30 DOSAGE FORMS WITH HIGH CONCENTRATION OF PRIDOPIDINE

Publications (1)

Publication Number Publication Date
MX2020002310A true MX2020002310A (es) 2020-09-17

Family

ID=63684470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002310A MX2020002310A (es) 2017-08-30 2018-08-30 Formas de dosificacion de alta concentracion de pridopidina.

Country Status (11)

Country Link
US (1) US11452694B2 (es)
EP (1) EP3675830A1 (es)
JP (1) JP2020532517A (es)
CN (1) CN111278431A (es)
AU (1) AU2018326596B2 (es)
BR (1) BR112020004045A2 (es)
CA (1) CA3073568A1 (es)
EA (1) EA202090542A1 (es)
IL (1) IL272934A (es)
MX (1) MX2020002310A (es)
WO (1) WO2019046568A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA3151507C (en) 2016-08-24 2024-05-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
HUE029790T2 (hu) 2004-10-13 2017-04-28 Teva Pharmaceuticals Int Gmbh Eljárás 4-(3-metánszulfonil-fenil)-l-N-propil-piperidin elõállítására
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
CA2780941C (en) * 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Immediate release tablet formulations
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
ES2879631T3 (es) * 2013-06-21 2021-11-22 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de la enfermedad de Huntington
EP4049657A1 (en) * 2014-01-22 2022-08-31 Prilenia Neurotherapeutics Ltd. Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
HUE060353T2 (hu) 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use

Also Published As

Publication number Publication date
US20200188305A1 (en) 2020-06-18
AU2018326596A1 (en) 2020-03-19
WO2019046568A1 (en) 2019-03-07
BR112020004045A2 (pt) 2020-09-01
CN111278431A (zh) 2020-06-12
JP2020532517A (ja) 2020-11-12
EA202090542A1 (ru) 2020-06-08
US11452694B2 (en) 2022-09-27
WO2019046568A8 (en) 2019-06-27
IL272934A (en) 2020-04-30
CA3073568A1 (en) 2019-03-07
EP3675830A1 (en) 2020-07-08
AU2018326596B2 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
MX2020002310A (es) Formas de dosificacion de alta concentracion de pridopidina.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201792591A1 (ru) Фармацевтические препараты
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
IN2013MU01696A (es)
EA201792595A1 (ru) Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
EA201992328A1 (ru) Фармацевтическая композиция, содержащая ленватиниба мезилат
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
MX2021001845A (es) Un medicamento combinado que comprende fenilefrina y paracetamol.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2016006927A (es) Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevencion de la dermatitis atopica.
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline